Abrocitinib

• A Long-Term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older with Moderate to Severe Eczema Recruiting
  2023-509124-18-00 Phase III 4 countries Pfizer Inc.
• A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age with Moderate-to-Severe Atopic Eczema Recruiting
  2023-509121-51-00 Phase III 4 countries Pfizer Inc.
• Optimization of atopic dermatitis treatment that requires second-line systemic therapy through multiomic predictive models of treatment resp… Recruiting
  2023-506165-62-00 Phase IV 1 country Hospital Universitario La Paz
• A clinical trial to evaluate safety, efficacy, and tolerability of abrocitinib in subjects with chronic hand eczema. Ended
  2023-504539-42-00 Phase II 1 country Innovaderm Research Inc.
• A study that allows patients from previous studies to continue on the medication. The aim of the study is to determine how safe and effectiv… Ended
  2023-508955-37-00 Phase III 3 countries Pfizer Inc.

Showing 1–5 of 5 trials